Fig. 2

Cumulative incidence of DVT aggravation in different groups. (A) The cumulative incidence of DVT aggravation between patients in 2022 and those in 2021; (B) In the 1:2 PSM cohorts, the relative risk for DVT aggravation between COVID-19 group and the control group; (C) In the 1:2 PSM cohorts, the risk incidences for DVT aggravation between COVID-19 group and the control group at C among patients who completed only 3 months anticoagulant therapy; (D). In the 1:2 PSM cohorts, no significant difference in the DVT control rate between the COVID-19 group and the control group at D among patients who received more than three months of anticoagulant therapy